 |
|
Bleeding Complications With Warfarin UseA Prevalent Adverse Effect Resulting in Regulatory Action
Diane K. Wysowski, PhD;
Parivash Nourjah, PhD;
Lynette Swartz, MEd, MBA
Arch Intern Med. 2007;167(13):1414-1419.
Background Warfarin sodium is widely used and causes bleeding; a review might suggest the need for regulatory action by the US Food and Drug Administration (FDA).
Methods We accessed warfarin prescriptions from the National Prescription Audit Plus database of IMS Health (Plymouth Meeting, Pennsylvania), adverse event reports submitted to the FDA, deaths due to therapeutic use of anticoagulants from vital statistics data, and warfarin bleeding complications from national hospital emergency department data.
Results The number of dispensed outpatient prescriptions for warfarin increased 45%, from 21 million in 1998 to nearly 31 million in 2004. The FDA's Adverse Event Reporting System indicated that warfarin is among the top 10 drugs with the largest number of serious adverse event reports submitted during the 1990 and 2000 decades. From US death certificates, anticoagulants ranked first in 2003 and 2004 in the number of total mentions of deaths for drugs causing "adverse effects in therapeutic use." Data from hospital emergency departments for 1999 through 2003 indicated that warfarin was associated with about 29 000 visits for bleeding complications per year, and it was among the drugs with the most visits. These data are consistent with literature reports of major bleeding frequencies for warfarin as high as 10% to 16%.
Conclusions Use of warfarin has increased, and bleeding from warfarin use is a prevalent reaction and an important cause of mortality. Consequently, a "black box" warning about warfarin's bleeding risk was added to the US product labeling in 2006. Physicians and nurses should tell patients to immediately report signs and symptoms of bleeding. A Medication Guide, which is required to be provided with each prescription, reinforces this message.
Author Affiliations: Office of Surveillance and Epidemiology, Food and Drug Administration, Silver Spring, Maryland.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati
What's this?
RELATED LETTERS
Bleeding Associated With Warfarin Use: Improving Outcomes
Megan Barkell
Arch Intern Med. 2008;168(2):236-237.
EXTRACT
| FULL TEXT
Bleeding Associated With Warfarin Use: Improving Outcomes—Reply
Diane K. Wysowski
Arch Intern Med. 2008;168(2):237.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Evaluating the impact of study-level factors on warfarin control in U.S.-based primary studies: A meta-analysis
Cios et al.
Am J Health Syst Pharm 2009;66:916-925.
ABSTRACT
| FULL TEXT
Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data
The International Warfarin Pharmacogenetics Consor
NEJM 2009;360:753-764.
ABSTRACT
| FULL TEXT
A Regulatory Science Perspective on Warfarin Therapy: A Pharmacogenetic Opportunity
Kim et al.
J Clin Pharmacol 2009;49:138-146.
ABSTRACT
| FULL TEXT
Alternatives to warfarin in atrial fibrillation: drugs and devices
Bayard et al.
Heart 2008;94:1113-1116.
FULL TEXT
Delivery of Optimized Anticoagulant Therapy: Consensus Statement from the Anticoagulation Forum
Garcia et al.
The Annals of Pharmacotherapy 2008;42:979-988.
ABSTRACT
| FULL TEXT
Outcomes Associated With Combined Antiplatelet and Anticoagulant Therapy
Johnson et al.
Chest 2008;133:948-954.
ABSTRACT
| FULL TEXT
Dual antiplatelet and oral anticoagulant therapy increasing use and precautions for a hazardous combination.
Hylek and Solarz
J Am Coll Cardiol Intv 2008;1:62-64.
FULL TEXT
Bleeding Associated With Warfarin Use: Improving Outcomes
Barkell
Arch Intern Med 2008;168:236-237.
FULL TEXT
Medication Use Leading to Emergency Department Visits for Adverse Drug Events in Older Adults
Budnitz et al.
ANN INTERN MED 2007;147:755-765.
ABSTRACT
| FULL TEXT
|
